Tresiba, also known by its generic name insulin degludec, is a long-acting insulin used in the management of both type 1 and type 2 diabetes. It is designed to help control blood sugar levels over a 24-hour period, with a duration of action that can last up to 42 hours, providing a more flexible dosing schedule compared to other insulins. Tresiba is administered via injection, typically once daily, and works by helping the body's cells absorb sugar (glucose) from the bloodstream to use as energy, thereby lowering blood sugar levels. It is part of a comprehensive treatment plan that includes diet, exercise, and regular blood sugar monitoring. As with any insulin therapy, the risk of hypoglycemia, or low blood sugar, is a potential side effect, making it important for users to closely follow their healthcare provider's instructions regarding dosing and monitoring.